Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters










Publication year range
1.
J Diabetes Complications ; 37(4): 108421, 2023 04.
Article in English | MEDLINE | ID: mdl-36905721

ABSTRACT

AIMS: The aim of this study was to investigate the effects of pioglitazone on reactive oxygen species (ROS), expressions/activities of MMPs and TIMP-2, and VSMC proliferation and vascular reactivity in high glucose (HG)-induced human saphenous vein (HSV) grafts. METHODS: HSV grafts (n = 10) obtained from patients undergoing CABG were incubated with 30 mM glucose and/or 10 µM pioglitazone or 0.1 % DMSO for 24 h after endothelium removal. ROS levels were examined by chemiluminescence assay, MMP-2,-9,-14, TIMP-2, and α-SMA expression/activity was determined by gelatine zymography/immunohistochemistry. Vascular reactivity to potassium chloride, noradrenaline, serotonin, prostaglandin F2α and papaverine was assessed in HSVs. RESULTS: HG induced superoxide anion (SA) (123 %) and other ROS levels (159 %), up-regulated MMP-2 expression (180 %)/activity (79 %), MMP-14 expression (24 %) and MMP-9 activity while down-regulating TIMP-2 expression (27 %). HG elevated total MMP-2/TIMP-2 ratio (483 %) and MMP-14/TIMP-2 ratio (78 %). However, HG plus pioglitazone inhibited SA (30 %) and other ROS levels (29 %), down-regulated MMP-2 expression (76 %)/activity (83 %), MMP-14 expression (38 %) and MMP-9 activity, while reversing TIMP-2 expression (44 %). HG plus pioglitazone decreased total MMP-2/TIMP-2 ratio (91 %) and MMP-14/TIMP-2 ratio (59 %). HG impaired contractions to all agents but pioglitazone improved them. CONCLUSIONS: Pioglitazone may contribute to the prevention of restenosis and maintaining vascular function in HSV grafts of DM patients undergoing CABG.


Subject(s)
Matrix Metalloproteinase 2 , Matrix Metalloproteinase 9 , Oxidative Stress , Pioglitazone , Saphenous Vein , Humans , Glucose/pharmacology , Glucose/metabolism , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 14/metabolism , Oxidative Stress/drug effects , Pioglitazone/pharmacology , Reactive Oxygen Species/metabolism , Saphenous Vein/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism , Tissue Inhibitor of Metalloproteinase-1/pharmacology , Tissue Inhibitor of Metalloproteinase-2/metabolism , Tissue Inhibitor of Metalloproteinase-2/pharmacology , Inflammation/metabolism
2.
Drug Deliv ; 29(1): 111-127, 2022 Dec.
Article in English | MEDLINE | ID: mdl-34964414

ABSTRACT

Naringenin, a flavonoid, possesses antiangiogenic potential and inhibits corneal neovascularization (CNV); however, its therapeutic use is restricted due to poor solubility and limited bioavailability. In this study, we developed a naringenin microemulsion (NAR-ME) for inhibiting CNV. NAR-ME formulation was composed of triacetin (oil phase), Cremophor RH40 (CRH40), PEG400, and water, its droplet size was 13.22 ± 0.13 nm with a narrow size distribution (0.112 ± 0.0014). The results demonstrated that NAR-ME released higher and permeated more drug than NAR suspension (NAR-Susp) in in vitro drug release and ex vivo corneal permeation study. Human corneal epithelial cells (HCECs) toxicity study showed no toxicity with NAR-ME, which is consistent with the result of ocular irritation study. NAR-ME had high bioavailability 1.45-fold, 2.15-fold, and 1.35-fold higher than NAR-Susp in the cornea, conjunctiva, and aqueous humor, respectively. Moreover, NAR-ME (0.5% NAR) presented efficacy comparable to that of dexamethasone (0.025%) in the inhibition of CNV in mice CNV model induced by alkali burning, resulting from the attenuation of corneal vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP-14) expression. In conclusion, the optimized NAR-ME formulation demonstrated excellent physicochemical properties and good tolerance, enhanced ocular bioavailability and corneal permeability. This formulation is promising, safe, and effective for the treatment of CNV.


Subject(s)
Corneal Neovascularization/pathology , Drug Carriers/chemistry , Emulsions/chemistry , Flavanones/pharmacology , Animals , Cell Line , Cell Survival , Chemistry, Pharmaceutical , Cornea/metabolism , Disease Models, Animal , Drug Liberation , Drug Stability , Flavanones/administration & dosage , Flavanones/adverse effects , Humans , Hydrogen-Ion Concentration , Male , Matrix Metalloproteinase 14/drug effects , Mice , Mice, Inbred BALB C , Ophthalmic Solutions , Particle Size , Rabbits , Surface Properties , Vascular Endothelial Growth Factor A/drug effects
3.
Endocr J ; 66(11): 1029-1037, 2019 Nov 28.
Article in English | MEDLINE | ID: mdl-31366822

ABSTRACT

In the present study, we investigate the effect of reduced cystathionine-γ-lyase (CSE) expression in high glucose induced metalloproteinases14 (MMP14) expression in adipocytes and visceral adipose tissues. Diabetic mice were prepared by injections of STZ and the expression of CSE, MMP14 in visceral adipose tissues were determined. Adipocytes were differentiated from 3T3-L1 cells and treated with high glucose (HG), H2S slow-releasing compound GYY4137 or transfected with CSE siRNA. Then the expression of CSE, MMP14 were determined by western blotting. CSE knockout mice were generated by crossing CSE+/- heterozygous mice and given intraperitoneally (i.p.) injections of GYY4137, and then the expression of CSE and MMP14 in visceral adipose tissues were determined by quantitative real-time PCR and western blotting. The following results were obtained from the study. In adipose tissues of diabetic mice, the mRNA and protein expression of MMP14 increased while the mRNA and protein expression of CSE decreased. In 3T3-L1 adipocytes, both HG DMEM and CSE siRNA transfection increased the mRNA and protein of MMP14. The addition of GYY4137 inhibited HG-induced upregulation of MMP14 expression. In CSE knockout mice, the mRNA and protein expression of MMP14 in adipose tissues increased, which could be inhibited by i.p. injections of GYY4137. In conclusion, high glucose increased the expression of MMP14 in adipocytes and visceral adipose tissues through inhibiting the expression of CSE.


Subject(s)
Adipocytes/metabolism , Cystathionine gamma-Lyase/genetics , Diabetes Mellitus, Experimental/genetics , Intra-Abdominal Fat/metabolism , Matrix Metalloproteinase 14/genetics , 3T3-L1 Cells , Adipocytes/drug effects , Animals , Blotting, Western , Cystathionine gamma-Lyase/drug effects , Cystathionine gamma-Lyase/metabolism , Diabetes Mellitus, Experimental/metabolism , Glucose/pharmacology , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 14/metabolism , Mice , Mice, Knockout , Morpholines/pharmacology , Organothiophosphorus Compounds/pharmacology , RNA, Messenger/drug effects , RNA, Messenger/metabolism , RNA, Small Interfering , Real-Time Polymerase Chain Reaction
4.
Bauru; s.n; 2017. 54 p. ilus, graf.
Thesis in English | BBO - Dentistry | ID: biblio-880409

ABSTRACT

A espécie vegetal Qualea grandiflora (QG), popularmente conhecida como "pauferro", "pau-terra-da-folha-grande", "pau-terra" ou "pau-de-tucano", muito comum no Cerrado brasileiro, é bem conhecida devido às suas variadas propriedades terapêuticas. Suas indicações incluem ações preventivas no aparecimento de lesões de mucosa gástrica, efeitos analgésicos, antibacterianos, anti-inflamatórios e antifúngicos. Assim, os componentes da QG poderiam ter alguma ação sobre moléculas amplamente envolvidas em processos angiogênicos e de desenvolvimento/reparo, como a Metaloproteinase de matriz 14 (MMP-14) e o Fator Induzido por hipóxia 1α (HIF-1alfa). Dessa maneira, o objetivo deste estudo foi investigar os efeitos do extrato hidroalcoólico das folhas de QG na viabilidade celular e expressão de MMP-14 e HIF-1alpha em culturas de fibroblastos da linhagem NIH/3T3 e pré-osteoblastos da linhagem MC3T3-E1. Para o teste de viabilidade celular e expressão das moléculas, concentrações de 0.1; 1.0 e 10 µg/mL do extrato hidroalcoólico das folhas de QG foram administrados por períodos de 24, 48, 72 e 96h. Após cada período, a viabilidade celular foi avaliada pelo método de redução de MTT e a análise da expressão das moléculas foi feita por meio da técnica de imunofluorescência. Os resultados mostram que o extrato de QG não promove redução da viabilidade celular de fibroblastos e pré-osteoblastos em concentrações até 10 µg/mL, nos períodos iniciais (24 e 48h). Porém, uma redução significativa da viabilidade pode ser verificada nos períodos de 72h e 96h para os fibroblastos e 96h para os pré-osteoblastos, expostos a mais alta concentração do extrato (10 µg/mL). O ensaio de imunofluorescência indica que o extrato, nas concentrações de 0.1; 1.0 e 10 µg/mL foi capaz de aumentar a expressão de MMP-14 e HIF-1alpha, em ambos os tipos celulares. Em conclusão, nossos resultados indicam que o extrato de QG exerce um efeito capaz de aumentar a expressão das duas moléculas em estudo (MMP-14 e HIF-1alpha), tanto para os fibroblastos da linhagem NIH/3T3 como para os pré- osteoblastos da linhagem MC3T3-E1. Assim, os compostos de QG podem apresentar potencial para serem utilizados como agentes terapêuticos moduladores da angiogênese, por meio do aumento da expressão de MMP-14 e HIF-1alpha.(AU)


The vegetable specie Qualea grandiflora (QG), popularly known as "pau-ferro", "pauterra-da-folha-grande", "pau-terra" or "pau-de-tucano", very common in the Brazilian Cerrado, is well known due to its varied therapeutic properties. Its indications include preventive actions in the appearance of lesions of gastric mucosa, analgesic, antibacterial, anti-inflammatory and antifungal effects. Thus, QG components could have some action on molecules widely involved in angiogenic and developmental / repair processes, such as Matrix metalloproteinase 14 (MMP-14) and HypoxiaInducible Factor-1α (HIF-1alpha). Thus, the objective of our study was to investigate the effects of QG hydroalcoholic extract on cell viability and expression of MMP-14 and HIF-1alpha in NIH/3T3 fibroblasts and MC3T3-E1 pre-osteoblasts cell lines. For the cell viability assay and expression of the molecules, concentrations of 0.1; 1.0 and 10 µg / mL of the hydroalcoholic extract of leaves of QG, were administered for periods of 24, 48, 72 and 96h. After each period, the cell viability was evaluated by MTT assay and the expression of the molecules was analyzed using the immunofluorescence technique. The results show that the QG extract does not promote reduction of the cellular viability of fibroblasts and pre-osteoblasts in concentrations up to 10 µg/mL in the initial periods (24 and 48h). However, a significant reduction in viability can be observed in 72h and 96h for fibroblasts and 96h for pre-osteoblasts exposed to the highest extract concentration (10 µg/mL). The immunofluorescence assay indicates that the extract, at concentrations of 0.1; 1.0 and 10 µg/mL was able to increase the expression of MMP-14 and HIF-1alpha in both cell types. In conclusion, our results indicate that the QG extract exerts an effect capable of increasing the expression of the two molecules under study (MMP-14 and HIF-1alpha) both for the NIH/3T3 fibroblasts as well as for the MC3T3-E1 pre-osteoblasts cells. Thus, the QG compounds could have potential to be used as angiogenesis modulating therapeutic agents, by increasing the expression of MMP-14 and HIF-1alpha.(AU)


Subject(s)
Animals , Cell Survival/drug effects , Hypoxia-Inducible Factor 1, alpha Subunit/drug effects , Magnoliopsida/chemistry , Matrix Metalloproteinase 14/drug effects , NIH 3T3 Cells/drug effects , Osteoblasts/drug effects , Plant Extracts/pharmacology , Cells, Cultured , Fluorescent Antibody Technique/methods , Hypoxia-Inducible Factor 1, alpha Subunit/analysis , Matrix Metalloproteinase 14/analysis , Muridae , Reproducibility of Results , Spectrophotometry/methods , Time Factors
5.
Arthritis Rheumatol ; 68(2): 521-31, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26315469

ABSTRACT

OBJECTIVE: In rheumatoid arthritis (RA), destruction of articular cartilage by the inflamed synovium is considered to be driven by increased activities of proteolytic enzymes, including matrix metalloproteinases (MMPs). The purpose of this study was to investigate the therapeutic potential of selective inhibition of membrane type 1 MMP (MT1-MMP) and its combination with tumor necrosis factor (TNF) blockage in mice with collagen-induced arthritis (CIA). METHODS: CIA was induced in DBA/1 mice by immunization with bovine type II collagen. From the onset of clinical arthritis, mice were treated with MT1-MMP selective inhibitory antibody DX-2400 and/or TNFR-Fc fusion protein. Disease progression was monitored daily, and serum, lymph nodes, and affected paws were collected at the end of the study for cytokine and histologic analyses. For in vitro analysis, bone marrow-derived macrophages were stimulated with lipopolysaccharide for 24 hours in the presence of DX-2400 and/or TNFR-Fc to analyze cytokine production and phenotype. RESULTS: DX-2400 treatment significantly reduced cartilage degradation and disease progression in mice with CIA. Importantly, when combined with TNF blockade, DX-2400 acted synergistically, inducing long-term benefit. DX-2400 also inhibited the up-regulation of interleukin-12 (IL-12)/IL-23 p40 via polarization toward an M2 phenotype in bone marrow-derived macrophages. Increased production of IL-17 induced by anti-TNF, which correlated with an incomplete response to anti-TNF, was abrogated by combined treatment with DX-2400 in CIA. CONCLUSION: Targeting MT1-MMP provides a potential strategy for joint protection, and its combination with TNF blockade may be particularly beneficial in RA patients with an inadequate response to anti-TNF therapy.


Subject(s)
Antibodies, Monoclonal/pharmacology , Arthritis, Experimental/immunology , Cartilage, Articular/drug effects , Etanercept/pharmacology , Interleukin-12 Subunit p40/drug effects , Macrophages/drug effects , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase Inhibitors/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Antibodies, Monoclonal, Humanized , Arthritis, Experimental/pathology , Cartilage, Articular/pathology , Disease Progression , In Vitro Techniques , Interferon-gamma/drug effects , Interferon-gamma/immunology , Interleukin-10/immunology , Interleukin-12 Subunit p40/immunology , Interleukin-17/immunology , Lipopolysaccharides/pharmacology , Lymph Nodes/drug effects , Lymph Nodes/immunology , Lymph Nodes/pathology , Macrophages/immunology , Matrix Metalloproteinase 14/immunology , Mice , Mice, Inbred DBA
6.
J Natl Cancer Inst ; 107(4)2015 Apr.
Article in English | MEDLINE | ID: mdl-25710962

ABSTRACT

BACKGROUND: Matrix metalloproteinase (MMP) 14 may mediate tumor progression through vascular and immune-modulatory effects. METHODS: Orthotopic murine breast tumors (4T1 and E0771 with high and low MMP14 expression, respectively; n = 5-10 per group) were treated with an anti-MMP14 inhibitory antibody (DX-2400), IgG control, fractionated radiation therapy, or their combination. We assessed primary tumor growth, transforming growth factor ß (TGFß) and inducible nitric oxide synthase (iNOS) expression, macrophage phenotype, and vascular parameters. A linear mixed model with repeated observations, with Mann-Whitney or analysis of variance with Bonferroni post hoc adjustment, was used to determine statistical significance. All statistical tests were two-sided. RESULTS: DX-2400 inhibited tumor growth compared with IgG control treatment, increased macrophage numbers, and shifted the macrophage phenotype towards antitumor M1-like. These effects were associated with a reduction in active TGFß and SMAD2/3 signaling. DX-2400 also transiently increased iNOS expression and tumor perfusion, reduced tissue hypoxia (median % area: control, 20.2%, interquartile range (IQR) = 6.4%-38.9%; DX-2400: 1.2%, IQR = 0.2%-3.2%, P = .044), and synergistically enhanced radiation therapy (days to grow to 800mm(3): control, 12 days, IQR = 9-13 days; DX-2400 plus radiation, 29 days, IQR = 26-30 days, P < .001) in the 4T1 model. The selective iNOS inhibitor, 1400W, abolished the effects of DX-2400 on vessel perfusion and radiotherapy. On the other hand, DX-2400 was not capable of inducing iNOS expression or synergizing with radiation in E0771 tumors. CONCLUSION: MMP14 blockade decreased immunosuppressive TGFß, polarized macrophages to an antitumor phenotype, increased iNOS, and improved tumor perfusion, resulting in reduced primary tumor growth and enhanced response to radiation therapy, especially in high MMP14-expressing tumors.


Subject(s)
Amidines/pharmacology , Antibodies, Monoclonal/pharmacology , Antineoplastic Agents/pharmacology , Benzylamines/pharmacology , Breast Neoplasms/metabolism , Breast Neoplasms/radiotherapy , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Macrophages/drug effects , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 14/metabolism , Nitric Oxide Synthase Type II/drug effects , Animals , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Breast Neoplasms/blood supply , Breast Neoplasms/drug therapy , Breast Neoplasms/immunology , Cell Line, Tumor , Dose Fractionation, Radiation , Female , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Humans , Immunoglobulin G/blood , Macrophages/enzymology , Mammary Neoplasms, Experimental , Mice , Neovascularization, Pathologic , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type II/metabolism , Phenotype , Signal Transduction/drug effects , Smad2 Protein/metabolism , Smad3 Protein/metabolism , Transforming Growth Factor beta/metabolism , Up-Regulation
7.
J Pediatr Gastroenterol Nutr ; 61(2): 194-9, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25539192

ABSTRACT

OBJECTIVES: Eosinophilic esophagitis (EoE) is a chronic, antigen-mediated disease in children and adults associated with substantial esophageal remodeling and fibrosis. The expression of the remodeling-associated matrix metalloproteinases (MMPs) has not been previously detailed in EoE. METHODS: MMP-2 and -14 expression and cellular localization were assessed using real-time quantitative polymerase chain reaction and immunohistochemistry/immunofluorescence in EoE fibroblasts, active and inactive pediatric EoE biopsies, and nondiseased control biopsies. The effect of transforming growth factor (TGF)-ß1 treatment on MMP-2 expression in cultured esophageal epithelial (HET1A) cells was analyzed. RESULTS: MMP-2 and -14 mRNA were expressed in EoE fibroblasts and biopsies. Proliferating epithelial cells produced MMP-14 more abundantly in EoE than in controls (P < 0.001) and the degree of epithelial MMP-14 expression correlated positively with basal zone hyperplasia (r = 0.65, P = 0.002). EoE lamina propria had higher numbers of MMP-2- and -14-positive cells (906 ±â€Š167 and 701 ±â€Š93 cells/mm²) as compared with controls (258 ±â€Š93 cells/mm², P < 0.01 and 232 ±â€Š54 cells/mm², P < 0.01), and MMP-14 expression correlated with the severity of fibrosis. Following therapy with topical corticosteroids, MMP-14 and -2 were significantly diminished (P < 0.01). TGF-ß1 increased the expression and secretion of MMP-2 from esophageal epithelial HET1A cells. CONCLUSIONS: MMP-2 and -14 are elevated in pediatric patients with EoE and significantly decrease following topical corticosteroid therapy. TGF-ß1 increases MMP-2 in esophageal epithelial cells. This alludes to previously unappreciated role for MMPs in EoE-associated esophageal remodeling and a potential positive feedback loop via TGF-ß1.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Eosinophilic Esophagitis/enzymology , Matrix Metalloproteinase 14/analysis , Matrix Metalloproteinase 2/analysis , Biopsy , Child , Eosinophilic Esophagitis/drug therapy , Eosinophilic Esophagitis/pathology , Epithelial Cells/enzymology , Epithelial Cells/pathology , Female , Fibroblasts/enzymology , Fluorescent Antibody Technique , Gene Expression/drug effects , Humans , Immunohistochemistry , Male , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 14/genetics , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 2/genetics , RNA, Messenger/analysis , Real-Time Polymerase Chain Reaction , Transforming Growth Factor beta1/pharmacology
8.
Circulation ; 124(24): 2725-34, 2011 Dec 13.
Article in English | MEDLINE | ID: mdl-22082680

ABSTRACT

BACKGROUND: Outcomes for organ transplantation are constantly improving because of advances in organ preservation, surgical techniques, immune clinical monitoring, and immunosuppressive treatment preventing acute transplant rejection. However, chronic rejection including transplant vasculopathy still limits long-term patient survival. Transplant vasculopathy is characterized by progressive neointimal hyperplasia leading to arterial stenosis and ischemic failure of the allograft. This work sought to decipher the manner in which the humoral immune response, mimicked by W6/32 anti-HLA antibody, contributes to transplant vasculopathy. METHODS AND RESULTS: Studies were performed in vitro on cultured human smooth muscle cells, ex vivo on human arterial segments, and in vivo in a model consisting of human arterial segments grafted into severe combined immunodeficiency/beige mice injected weekly with anti-HLA antibodies. We report that anti-HLA antibodies are mitogenic for smooth muscle cells through a signaling mechanism implicating matrix metalloproteinases (MMPs) (membrane type 1 MMP and MMP2) and neutral sphingomyelinase-2. This mitogenic signaling and subsequent DNA synthesis are blocked in smooth muscle cells silenced for MMP2 or for neutral sphingomyelinase-2 by small interfering RNAs, in smooth muscle cells transfected with a vector coding for a dominant-negative form of membrane type 1 MMP, and after treatment by pharmacological inhibitors of MMPs (Ro28-2653) or neutral sphingomyelinase-2 (GW4869). In vivo, Ro28-2653 and GW4869 reduced the intimal thickening induced by anti-HLA antibodies in human mesenteric arteries grafted into severe combined immunodeficiency/beige mice. CONCLUSIONS: These data highlight a crucial role for MMP2 and neutral sphingomyelinase-2 in vasculopathy triggered by a humoral immune response and open new perspectives for preventing transplant vasculopathy with the use of MMP and neutral sphingomyelinase inhibitors, in addition to conventional immunosuppression.


Subject(s)
Antibodies, Anti-Idiotypic/pharmacology , Arteries/transplantation , HLA Antigens/immunology , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase 2/metabolism , Sphingomyelin Phosphodiesterase/metabolism , Vascular Diseases/physiopathology , Aniline Compounds/pharmacology , Animals , Antibodies, Anti-Idiotypic/adverse effects , Arteries/pathology , Arteries/physiopathology , Benzylidene Compounds/pharmacology , Cells, Cultured , Constriction, Pathologic/etiology , Constriction, Pathologic/physiopathology , Disease Models, Animal , Humans , Hyperplasia/etiology , Hyperplasia/physiopathology , In Vitro Techniques , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase Inhibitors , Mice , Mice, SCID , Models, Animal , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Neointima/pathology , Neointima/physiopathology , Piperazines/pharmacology , Pyrimidines/pharmacology , RNA, Small Interfering/pharmacology , Sphingomyelin Phosphodiesterase/antagonists & inhibitors , Sphingomyelin Phosphodiesterase/drug effects , Vascular Diseases/etiology , Vascular Grafting
9.
Oral Dis ; 17(3): 291-7, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20860766

ABSTRACT

OBJECTIVE: Osteonecrosis of the jaw is a serious complication of bisphosphonate treatment for which the pathophysiology is unknown. The purpose of this study was to investigate whether in vivo zoledronic acid (ZA) induces alterations in cell proliferation, apoptosis, and matrix metalloproteinases (MMPs) expression in oral mucosal epithelial cells. METHODS: One-year-old dogs were either untreated (control group) or given high doses of intravenous ZA (ZA group) for 3 months. The doses of ZA were equivalent to those given to cancer patients, yet were administered two times more frequently (every 2 weeks). Mucosal tissues were assessed immunohistochemically for cell proliferation (proliferating cell nuclear antigen, PCNA), matrix metalloproteinase (MMP) expression, and apoptosis (caspase 3 and TUNEL). RESULTS: There were no significant differences between the groups with respect to PCNA, MMP-2, MMP-14, and TUNEL positive cells. However, the expression of MMP-9 was significantly higher in the control group than in the ZA group (P < 0.05), whereas the expression of caspase 3 was significantly lower in the control group than in the ZA group (P < 0.05). CONCLUSION: These results suggest that high doses of ZA resulted in higher levels of apoptosis and lower levels of MMP-9 in the oral epithelial cells supporting the idea of bisphosphonate treatment affects the oral mucosa.


Subject(s)
Bone Density Conservation Agents/pharmacology , Diphosphonates/pharmacology , Imidazoles/pharmacology , Mouth Mucosa/drug effects , Animals , Apoptosis/drug effects , Bone Density Conservation Agents/administration & dosage , Caspase 3/drug effects , Cell Proliferation/drug effects , Diphosphonates/administration & dosage , Dogs , Epithelial Cells/drug effects , Female , Imidazoles/administration & dosage , Immunohistochemistry , In Situ Nick-End Labeling , Injections, Intravenous , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 9/drug effects , Models, Animal , Mouth Mucosa/cytology , Proliferating Cell Nuclear Antigen/drug effects , Zoledronic Acid
10.
J Periodontol ; 82(7): 1071-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21142980

ABSTRACT

BACKGROUND: Members of the matrix metalloproteinase (MMP) family have been shown to be involved in periodontal disease. Risk factors for periodontal disease include tobacco smoking. Cigarette smoke condensate (CSC) is comprised of thousands of chemicals. Nicotine is one of the active components in tobacco. This study compares the effects of CSC and nicotine at the level in CSC on the collagen-degrading ability of human gingival fibroblasts (HGFs) and the expression of selected MMPs and tissue inhibitors of metalloproteinases (TIMPs). METHODS: HGFs were seeded in six-well collagen-coated plates, exposed to 100 µg/mL (2.4 µg/mL nicotine) of CSC or 2.4 µg/mL nicotine for 3 days, and then collagen degradation was analyzed. After 3 days exposure to CSC or nicotine, the conditioned media from HGFs was collected and the membrane proteins were extracted for gelatin zymography and Western blot analyses. The mRNA levels of MMP-2, MMP-14, and TIMP-2 were measured by reverse transcription-polymerase chain reaction. RESULTS: The CSC increased collagen degradation, and increased the levels of TIMP-2, MMP-14, and the active MMP-2 in the membrane extracts, and their mRNA levels. CSC also increased the level of active MMP-2 in the conditioned media. Nicotine at the level in CSC (2.4 µg/mL) had little influence on collagen degradation, as well as on the protein and mRNA levels of MMP-2, MMP-14, and TIMP-2. CONCLUSIONS: CSC may increase HGF-mediated collagen degradation by affecting membrane-associated MMPs and TIMPs.


Subject(s)
Collagen Type I/drug effects , Fibroblasts/drug effects , Gingiva/drug effects , Nicotiana , Nicotine/pharmacology , Smoke , Blotting, Western , Cells, Cultured , Collagen Type I/analysis , Complex Mixtures/pharmacology , Culture Media, Conditioned , Culture Media, Serum-Free , Cyclophilins/analysis , Cyclophilins/drug effects , Enzyme Precursors/analysis , Enzyme Precursors/drug effects , Fibroblasts/metabolism , Gelatinases/analysis , Gelatinases/drug effects , Gingiva/cytology , Humans , Matrix Metalloproteinase 14/analysis , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinases, Membrane-Associated/analysis , Matrix Metalloproteinases, Membrane-Associated/drug effects , Protease Inhibitors/analysis , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinase-2/analysis , Tissue Inhibitor of Metalloproteinase-2/drug effects , Tissue Inhibitor of Metalloproteinases/analysis , Tissue Inhibitor of Metalloproteinases/drug effects
11.
Bioorg Med Chem Lett ; 20(12): 3557-60, 2010 Jun 15.
Article in English | MEDLINE | ID: mdl-20529684

ABSTRACT

A series of phenyl piperidine alpha-sulfone hydroxamate derivatives has been prepared utilizing a combination of solution-phase and resin-bound library technologies to afford compounds that are potent and highly selective for MMP-13, are dual-sparing of MMP-1 and MMP-14 (MT1-MMP) and exhibit oral bioavailability in rats.


Subject(s)
Matrix Metalloproteinase Inhibitors , Administration, Oral , Animals , Biological Availability , Hydroxamic Acids/administration & dosage , Matrix Metalloproteinase 1/drug effects , Matrix Metalloproteinase 14/drug effects , Piperidines , Rats , Small Molecule Libraries , Solubility , Substrate Specificity , Sulfones
12.
Int J Cancer ; 126(5): 1055-66, 2010 Mar 01.
Article in English | MEDLINE | ID: mdl-19551865

ABSTRACT

We previously demonstrated that the CNYYSNS peptide derived from tumstatin inhibited in vivo tumor progression. The YSNS motif formed a beta-turn crucial for biological activity. More recently, a YSNSG cyclopeptide with a constrained beta-turn on the YSNS residues was designed. Intraperitoneal administration of the YSNSG cyclopeptide inhibited in vivo melanoma progression more efficiently than the native linear peptide. In the present article, we showed that the YSNSG cyclopeptide also triggered an inhibition of in vivo tumor neovascularization and we further analyzed its in vitroantiangiogenic effect. The YSNSG cyclopeptide did not alter endothelial cell proliferation but inhibited cell migration by 83% in an in vitro wound healing model. The inhibition was mediated by a decrease in active MT1-MMP at the migration front as well as a decrease in u-PA and u-PAR expression. The cyclopeptide also altered beta1-integrin distribution in endothelial cell lamellipodia, induced a strong decrease in the phosphorylated focal adhesion kinase (p125(FAK)), disorganized F-actin stress fibers and decreased the number of lamellipodia, resulting in a non migratory phenotype. Our results confirm the YSNSG cyclopeptide as a potent antitumor agent, through both the inhibition of invasive properties of tumor cells and the antiangiogenic activity.


Subject(s)
Antineoplastic Agents/pharmacology , Cell Movement/drug effects , Endothelial Cells/drug effects , Neovascularization, Pathologic/drug therapy , Peptides, Cyclic/pharmacology , Animals , Autoantigens/chemistry , Blotting, Western , Cell Proliferation/drug effects , Collagen Type IV/chemistry , Down-Regulation , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 14/metabolism , Melanoma, Experimental/drug therapy , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Receptors, Urokinase Plasminogen Activator/drug effects , Receptors, Urokinase Plasminogen Activator/metabolism , Urokinase-Type Plasminogen Activator/drug effects , Urokinase-Type Plasminogen Activator/metabolism , Xenograft Model Antitumor Assays
13.
J Periodontal Res ; 44(1): 73-80, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19515020

ABSTRACT

BACKGROUND AND OBJECTIVES: Membrane type 1-matrix metalloproteinase (MT1-MMP) is a collagenolytic enzyme involved in connective tissue remodeling. In periodontal tissues, either cytokines or growth factors regulate the production of proteolytic enzymes. Mice deficient in epidermal growth factor receptor (EGFR) show a reduced expression of MT1-MMP, suggesting that this receptor may play an important role in MT1-MMP production. The present study evaluated the role of the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and EGFR in the production of MT1-MMP in gingival fibroblasts. MATERIAL AND METHODS: Primary cultures of human gingival fibroblasts were cultured over plastic or a type I collagen matrix and stimulated with TNF-alpha and EGF. A selective EGFR inhibitor (AG1478) was used to interfere with this signaling pathway. Production of MT1-MMP and activation of proMMP-2 were studied using Western blot and gelatin zymography, respectively. Activation of EGFR signaling was assessed through immunoprecipitation and Western blot. Expression of EGFR ligands was determined through reverse transcriptase-polymerase chain reaction. RESULTS: Treatment of gingival fibroblasts cultured over a collagen matrix with TNF-alpha stimulated proMMP-2 activation and MT1-MMP production. However, after using AG1478, both responses were inhibited. Tumor necrosis factor-alpha induced EGFR transactivation and stimulated the expression of the mRNA for the EGFR ligands heparin binding-epidermal growth factor (HB-EGF) and transforming growth factor-alpha (TGF-alpha). CONCLUSIONS: The present study shows that TNF-alpha may stimulate MT1-MMP production through transactivation of EGFR. Tumor necrosis factor-alpha may also modulate the expression of the EGFR ligands TGF-alpha and HB-EGF. Production of MT1-MMP by TNF-alpha requires interaction with EGFR, suggesting that tissue remodeling is controlled by cross-communication between diverse signaling pathways in gingival fibroblasts.


Subject(s)
ErbB Receptors/drug effects , Fibroblasts/drug effects , Gingiva/drug effects , Matrix Metalloproteinase 14/drug effects , Signal Transduction/drug effects , Tumor Necrosis Factor-alpha/pharmacology , Cells, Cultured , Collagen Type I/pharmacology , Culture Media , Enzyme Inhibitors/pharmacology , Enzyme Precursors/drug effects , Epidermal Growth Factor/pharmacology , ErbB Receptors/antagonists & inhibitors , Fibroblasts/enzymology , Gelatinases/drug effects , Gingiva/cytology , Gingiva/enzymology , Heparin/analysis , Heparin-binding EGF-like Growth Factor , Humans , Intercellular Signaling Peptides and Proteins/analysis , Ligands , Phosphorylation , Protein Tyrosine Phosphatases/antagonists & inhibitors , Quinazolines , Receptors, Cell Surface/analysis , Transcriptional Activation/drug effects , Transforming Growth Factor alpha/drug effects , Tyrphostins/pharmacology
14.
J Clin Invest ; 119(3): 492-503, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19197139

ABSTRACT

The mechanisms governing hematopoietic progenitor cell mobilization are not fully understood. We report higher membrane type 1-MMP (MT1-MMP) and lower expression of the MT1-MMP inhibitor, reversion-inducing cysteine-rich protein with Kazal motifs (RECK), on isolated circulating human CD34+ progenitor cells compared with immature BM cells. The expression of MT1-MMP correlated with clinical mobilization of CD34+ cells in healthy donors and patients with lymphoid malignancies. Treatment with G-CSF further increased MT1-MMP and decreased RECK expression in human and murine hematopoietic cells in a PI3K/Akt-dependent manner, resulting in elevated MT1-MMP activity. Blocking MT1-MMP function by Abs or siRNAs impaired chemotaxis and homing of G-CSF-mobilized human CD34+ progenitors. The mobilization of immature and maturing human progenitors in chimeric NOD/SCID mice by G-CSF was inhibited by anti-MT1-MMP treatment, while RECK neutralization promoted motility and egress of BM CD34+ cells. BM c-kit+ cells from MT1-MMP-deficient mice also exhibited inferior chemotaxis, reduced homing and engraftment capacities, and impaired G-CSF-induced mobilization in murine chimeras. Membranal CD44 cleavage by MT1-MMP was enhanced following G-CSF treatment, reducing CD34+ cell adhesion. Accordingly, CD44-deficient mice had a higher frequency of circulating progenitors. Our results reveal that the motility, adhesion, homing, and mobilization of human hematopoietic progenitor cells are regulated in a cell-autonomous manner by dynamic and opposite changes in MT1-MMP and RECK expression.


Subject(s)
Antigens, CD34/analysis , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cells/physiology , Matrix Metalloproteinase 14/genetics , Membrane Glycoproteins/genetics , Animals , Antigens, CD/analysis , Bone Marrow Cells/physiology , Cell Movement/physiology , Chemotaxis , Chimera/genetics , GPI-Linked Proteins , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cells/drug effects , Hematopoietic Stem Cells/immunology , Humans , Matrix Metalloproteinase 14/deficiency , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 14/metabolism , Membrane Glycoproteins/drug effects , Membrane Glycoproteins/metabolism , Mice , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , RNA, Messenger/genetics , RNA, Small Interfering/genetics
15.
Eur J Pharmacol ; 599(1-3): 24-31, 2008 Dec 03.
Article in English | MEDLINE | ID: mdl-18851960

ABSTRACT

Human adipose tissue-derived stromal cells (hADSCs) demonstrate promising potential in various clinical applications, including the transplantation to regenerate injured or degenerative tissues. The migration of engrafted hADSCs to the correct site of injure is essential for the curative effect of stem cell therapy. We found that protocatechuic acid (PCA) from Alpinia (A.) oxyphylla could promote the migration capacity of hADSCs through transwell coated with gelatin in vitro. PCA enhanced the cell migration rate in a dose-dependent and time-dependent manner. Meanwhile, RT-PCR and quantitative RT-PCR analysis revealed the elevation of membrane-type matrix metalloproteinase-1 (MT1-MMP) mRNA expression in 1.5 mM PCA-treated hADSCs. In the supernatants of these cells, the active matrix metalloproteinase-2 (MMP-2) increased compared with control cells with zymography. Moreover, the promotion of cell migration by PCA could be effectively and obviously inhibited by anti-MT1-MMP or anti-MMP-2 antibodies. Furthermore, flow cytometric analysis of the cell surface antigens, osteogenic induction, adipogenic induction and cardiomyocyte-like cell induction demonstrated that hADSCs retained their functional characteristics of multipotential mesenchymal progenitors after PCA treatment. These results suggest that PCA from A. oxyphylla promote the migration of hADSCs in vitro, which is partially due to the increased expression of MT1-MMP and the promotion of MMP-2 zymogen activation.


Subject(s)
Alpinia/chemistry , Cell Movement/drug effects , Hydroxybenzoates/pharmacology , Matrix Metalloproteinase 14/drug effects , Adipose Tissue/cytology , Adipose Tissue/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Flow Cytometry , Gene Expression Regulation, Enzymologic/drug effects , Humans , Hydroxybenzoates/administration & dosage , Hydroxybenzoates/isolation & purification , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase 2/drug effects , Matrix Metalloproteinase 2/metabolism , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Stromal Cells/drug effects , Stromal Cells/metabolism , Time Factors
16.
J Periodontol ; 79(10): 1934-41, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18834249

ABSTRACT

BACKGROUND: Matrix metalloproteinases (MMPs) play important roles in tissue-destruction mechanisms-associated periodontitis. MMP-8 and -13 are the predominant collagenases that are important in the extracellular matrix degradation in periodontal tissues. MMP-14 is a membrane-type MMP, whereas laminin-5 indicates basal membrane modification and epithelial induction. The purpose of the present study was to evaluate the effects of celecoxib and omega-3 fatty acid administration on the gingival tissue expression of MMP-8, -13, and -14, tissue inhibitor of MMP (TIMP)-1, and laminin (Ln)-5gamma2-chain in rat experimental periodontitis induced by Escherichia coli endotoxin (lipopolysaccharide [LPS]). METHODS: Experimental periodontitis was induced in rats by repeated LPS injection. Fifty-one adult male Sprague-Dawley rats were divided into six study groups: saline control, LPS, LPS + celecoxib, LPS + therapeutic omega-3 (TO3), prophylactic omega-3 + LPS + omega-3 (P+TO3), and LPS + celecoxib + omega-3 fatty acid. Celecoxib and omega-3 fatty acid were given as a single agent or as combination therapy for 14 days. On day 15, all rats were sacrificed, and gingival tissues were analyzed immunohistochemically for the expression of MMP-8, -13, and -14, TIMP-1, and Ln-5gamma2-chain. Alveolar bone loss was evaluated morphometrically under a stereomicroscope. Data were tested statistically by Kruskal-Wallis and Mann-Whitney tests and Spearman correlation analysis. RESULTS: Alveolar bone loss was significantly higher in all study groups compared to the saline control group (all P <0.01). MMP-8 expression was significantly higher in the LPS group than in the saline group (P = 0.001). Very low expression of MMP-8 was found in the celecoxib, P+TO3, and combination groups. TO3 increased TIMP-1 expression significantly compared to the LPS group (P <0.05). Individual celecoxib and P+TO3 administration increased MMP-14 significantly compared to saline control and LPS groups (P <0.05). No significant differences were found among the study groups with regard to Ln-5gamma2-chain and MMP-13 expressions (P >0.05). CONCLUSIONS: Selective cyclooxygenase-2 inhibitor, prophylactic omega-3 fatty acid, and a combination of these two agents can inhibit gingival tissue MMP-8 expression. Moreover, the individual administration of therapeutic omega-3 may increase gingival TIMP-1 expression in contrast to no effect on MMP-8, -13, and -14 expressions in experimental periodontitis. These experimental findings in a rat model of LPS-induced periodontitis need to be verified by clinical human studies.


Subject(s)
Cyclooxygenase 2 Inhibitors/therapeutic use , Fatty Acids, Omega-3/therapeutic use , Laminin/drug effects , Matrix Metalloproteinases/drug effects , Periodontitis/drug therapy , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Tissue Inhibitor of Metalloproteinase-1/drug effects , Alveolar Bone Loss/drug therapy , Alveolar Bone Loss/enzymology , Alveolar Bone Loss/pathology , Animals , Celecoxib , Disease Models, Animal , Drug Combinations , Escherichia coli , Gingiva/drug effects , Gingiva/enzymology , Gingivitis/drug therapy , Gingivitis/enzymology , Gingivitis/pathology , Laminin/analysis , Lipopolysaccharides , Male , Matrix Metalloproteinase 13/analysis , Matrix Metalloproteinase 13/drug effects , Matrix Metalloproteinase 14/analysis , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 8/analysis , Matrix Metalloproteinase 8/drug effects , Matrix Metalloproteinases/analysis , Periodontitis/enzymology , Periodontitis/pathology , Rats , Rats, Sprague-Dawley , Tissue Inhibitor of Metalloproteinase-1/analysis
17.
J Toxicol Environ Health A ; 71(16): 1053-5, 2008.
Article in English | MEDLINE | ID: mdl-18569616

ABSTRACT

This study focused on the effects of arsenic (As) on fibroblast-derived matrix metalloproteinase (MMP)-2 and -14 levels, as these proteins were reported to be associated with tumor progression. Arsenic was found to promote production of the fibroblast-derived active form of MMP-2. Further, As at 100 or 1000 microM increased MMP-14 expression levels in fibroblasts. In addition, 1000 microM mercury (Hg) but not As increased pro-MMP-2 protein, which is involved in the conversion of the proenzyme into its active form. Since MMP-14 is an activator of pro-MMP-2, data suggest that As promotes production of fibroblast-derived active form of MMP-2 through increased expression of MMP-14. Evidence indicates that As appeared to be less effective than Hg in the conversion of pro-MMP-2 into its active form.


Subject(s)
Arsenic/pharmacology , Fibroblasts/metabolism , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 2/drug effects , Cells, Cultured , Enzyme Activation/drug effects , Fibroblasts/enzymology , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase 2/metabolism
18.
Cardiovasc Res ; 79(1): 34-41, 2008 Jul 01.
Article in English | MEDLINE | ID: mdl-18310679

ABSTRACT

AIMS: Expression and activation of matrix metalloproteinase (MMP)-2 play pivotal roles in the migration and invasion of human aortic vascular smooth muscle cells (VSMC) originating from normal human tissue, which is strongly linked to atherosclerosis. The present study investigated the possible inhibitory effects of cocoa procyanidin on thrombin-induced expression and activation of MMP-2 in VSMC. METHODS AND RESULTS: Cocoa procyanidin fraction (CPF) and procyanidin B2, one of major procyanidins in cocoa (3 microg/mL and 5 microM, respectively), strongly inhibited thrombin-induced activation and expression of pro-MMP-2 in VSMC, as determined by zymography. The thrombin-induced invasion and migration of VSMC were inhibited by CPF or procyanidin B2 (P < 0.05), as assessed by a modified Boyden chamber and wound healing assays, respectively. An enzymatic assay data demonstrated that CPF and procyanidin B2 directly inhibited membrane type-1 (MT1)-MMP activity (P < 0.05), and this inhibition of CPF was greater than those of red wine polyphenols. Western blot data showed that CPF and procyanidin B2 inhibited thrombin-induced phosphorylation of extracellular signal-regulated protein kinase but not mitogen-activated protein kinase kinase (MEK) in VSMC. Kinase and pull-down data revealed that CPF and procyanidin B2 inhibited MEK1 activity and directly bound with glutathione-S-transferase-MEK1. In addition, the thrombin-induced invasion and migration and the activation and expression of pro-MMP-2 in VSMC were attenuated by U0126 (a well-known inhibitor of MEK1). CONCLUSION: Cocoa procyanidins are potent inhibitors of MEK and MT1-MMP, and subsequently inhibit the expression and activation of pro-MMP-2, and also the invasion and migration of VSMC, which may in part explain the molecular action of antiatherosclerotic effects of cocoa.


Subject(s)
Cacao , MAP Kinase Kinase 1/metabolism , Matrix Metalloproteinase 14/metabolism , Matrix Metalloproteinase 2/metabolism , Muscle, Smooth, Vascular/metabolism , Plant Preparations/pharmacology , Proanthocyanidins/pharmacology , Aorta/cytology , Aorta/drug effects , Aorta/metabolism , Biflavonoids/pharmacology , Catechin/pharmacology , Cell Movement/drug effects , Cells, Cultured , Extracellular Signal-Regulated MAP Kinases/drug effects , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , MAP Kinase Kinase 1/drug effects , Matrix Metalloproteinase 14/drug effects , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Thrombin/pharmacology
19.
Int J Cancer ; 121(12): 2808-14, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-17721919

ABSTRACT

Tumor progress depends on the proliferation of cancer cells, their interactions with stroma and the proteolytic action of enzymes. Colon cancer is c-kit positive and responsive to the specific tyrosine kinase inhibitor imatinib. We investigated the effect of imatinib on the proliferation of a panel of epithelial colon cancer cell lines in presence and absence of the antimetabolite 5-FU, and the effect of conditioned media (CM) derived from colon stromal fibroblasts with and without previous exposure to imatinib. The effects of imatinib on gene expression of MMPs and TIMPs were also studied. Imatinib effectively inhibited the proliferation of all cell lines, showing IC(50) from 0.3 to 3 microM. Its combination with 5-FU significantly enhances the growth inhibition of the highly tumourigenic HT-29 cells. CM derived from stromal fibroblasts induced the proliferation of the HT-29 cells; this stimulatory effect was abolished upon treatment with CM obtained after exposure of fibroblasts to imatinib. Gene expression of MT1-, MT2-MMP and MMP-7 was also inhibited depending on the cell line, whereas that of TIMP-2 was not affected. CM stimulated MT1-MMP protein expression by HT-29; this stimulatory effect was suppressed in the presence of imatinib. Activation of pro-MMP2 to MMP2 in culture medium of HT-29 treated with CM was increased and this activity was inhibited in presence of imatinib. The obtained data showed that imatinib is a powerful inhibitor of human colon cancer cell growth and effectively suppresses the stromal-induced stimulation of cancer cell growth and activation of proMMP2. Further studies are warranted to evaluate the in vivo effects.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Colonic Neoplasms/drug therapy , Enzyme Precursors/metabolism , Fluorouracil/pharmacology , Gelatinases/metabolism , Matrix Metalloproteinase 14/metabolism , Metalloendopeptidases/metabolism , Piperazines/pharmacology , Pyrimidines/pharmacology , Antimetabolites, Antineoplastic/pharmacology , Apoptosis/drug effects , Benzamides , Blotting, Western , Cell Line, Tumor , Cell Proliferation/drug effects , Enzyme Activation/drug effects , Enzyme Precursors/drug effects , Gelatinases/drug effects , Gene Expression Regulation, Enzymologic/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Imatinib Mesylate , Matrix Metalloproteinase 14/drug effects , Metalloendopeptidases/drug effects , Proto-Oncogene Proteins c-kit/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinases/metabolism
20.
Stem Cells ; 24(8): 1892-903, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16690780

ABSTRACT

Human mesenchymal stem cells (hMSCs) exhibit the potential to contribute to a wide variety of endogenous organ tissue repair. However, the signals governing hMSC mobilization out of the bone marrow, release into the bloodstream, and migration/invasion into the target tissue are largely unknown. Since canonical Wnt signaling regulates not only tumor but also various stem cell attributes, we hypothesized that this signal transduction pathway might also be involved in governing the transmigration of hMSCs through human extracellular matrix (ECM). Stimulation of hMSCs with recombinant Wnt3a or LiCl resulted in the accumulation of the transcriptional activator beta-catenin, its translocation into the nucleus, and the upregulation of typical Wnt target genes such as cyclin D1 and membrane-type matrix metalloproteinase-1 (MT1-MMP). Moreover, both stimuli significantly enhanced hMSC proliferation up to 40%. In addition, an increase of more than twofold in the ability of hMSCs to transmigrate through Transwell filters coated with human ECM was observed. In a reverse approach, Wnt signaling in hMSCs was inhibited by knocking down the expression of either beta-catenin or low-density lipoprotein receptor-related protein 5 using RNA interference technology. These inhibition strategies resulted in downregulation of the Wnt target genes cyclin D1 and MT1-MMP, in a reduced proliferation rate, and in a strikingly diminished invasion capacity (64% and 52%). Taken together, this study provides for the first time decisive evidence that canonical Wnt signaling is critically involved in the regulation of the proliferation, as well as of the migration/invasion capacity of hMSCs, representing essential stem cell features indispensable during tissue regeneration processes.


Subject(s)
Cell Movement/physiology , Mesenchymal Stem Cells/physiology , Signal Transduction/physiology , Wnt Proteins/metabolism , Cell Proliferation/drug effects , Cells, Cultured , Cyclin D , Cyclins/drug effects , Cyclins/genetics , Cyclins/metabolism , Humans , LDL-Receptor Related Proteins/drug effects , LDL-Receptor Related Proteins/genetics , LDL-Receptor Related Proteins/metabolism , Lithium Chloride/chemistry , Lithium Chloride/metabolism , Low Density Lipoprotein Receptor-Related Protein-5 , Matrix Metalloproteinase 14/drug effects , Matrix Metalloproteinase 14/genetics , Matrix Metalloproteinase 14/metabolism , Mesenchymal Stem Cells/cytology , Molecular Sequence Data , RNA Interference , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/genetics , Wnt Proteins/antagonists & inhibitors , Wnt Proteins/genetics , Wnt3 Protein , Wnt3A Protein , beta Catenin/drug effects , beta Catenin/genetics , beta Catenin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...